



# Identification of a Family of *Vibrio* Type III Secretion System Effectors That Contain a Conserved Serine/Threonine Kinase Domain

N. Plaza,<sup>a,b</sup> I. M. Urrutia,<sup>b</sup> K. Garcia,<sup>a</sup>  M. K. Waldor,<sup>c,d,e</sup>  C. J. Blondel<sup>b</sup>

<sup>a</sup>Instituto de Ciencias Biomédicas, Facultad de Ciencias de la Salud, Universidad Autónoma de Chile, Santiago, Chile

<sup>b</sup>Instituto de Ciencias Biomédicas, Facultad de Medicina y Facultad de Ciencias de la Vida, Universidad Andrés Bello, Santiago, Chile

<sup>c</sup>Division of Infectious Diseases, Brigham & Women's Hospital, Boston, Massachusetts, USA

<sup>d</sup>Department of Microbiology, Harvard Medical School, Boston, Massachusetts, USA

<sup>e</sup>Howard Hughes Medical Institute, Boston, Massachusetts, USA

**ABSTRACT** *Vibrio parahaemolyticus* is a marine Gram-negative bacterium that is a leading cause of seafood-borne gastroenteritis. Pandemic strains of *V. parahaemolyticus* rely on a specialized protein secretion machinery known as the type III secretion system 2 (T3SS2) to cause disease. The T3SS2 mediates the delivery of effector proteins into the cytosol of infected cells, where they subvert multiple cellular pathways. Here, we identify a new T3SS2 effector protein encoded by VPA1328 (VP\_RS21530) in *V. parahaemolyticus* RIMD2210633. Bioinformatic analysis revealed that VPA1328 is part of a larger family of uncharacterized T3SS effector proteins with homology to the VopG effector protein in *Vibrio cholerae* AM-19226. These VopG-like proteins are found in many but not all T3SS2 gene clusters and are distributed among diverse *Vibrio* species, including *V. parahaemolyticus*, *V. cholerae*, *V. mimicus*, and *V. diabolicus* and also in *Shewanella baltica*. Structure-based prediction analyses uncovered the presence of a conserved C-terminal kinase domain in VopG orthologs, similar to the serine/threonine kinase domain found in the NleH family of T3SS effector proteins. However, in contrast to NleH effector proteins, in tissue culture-based infections, VopG did not impede host cell death or suppress interleukin 8 (IL-8) secretion, suggesting a yet undefined role for VopG during *V. parahaemolyticus* infection. Collectively, our work reveals that VopG effector proteins, a new family of likely serine/threonine kinases, is widely distributed in the T3SS2 effector armamentarium among marine bacteria.

**IMPORTANCE** *Vibrio parahaemolyticus* is the leading bacterial cause of seafood-borne gastroenteritis worldwide. The pathogen relies on a type III secretion system to deliver a variety of effector proteins into the cytosol of infected cells to subvert cellular function. In this study, we identified a novel *Vibrio parahaemolyticus* effector protein that is similar to the VopG effector of *Vibrio cholerae*. VopG-like effectors were found in diverse *Vibrio* species and contain a conserved serine/threonine kinase domain that bears similarity to the kinase domain in the enterohemorrhagic *Escherichia coli* (EHEC) and *Shigella* NleH effectors that manipulate host cell survival pathways and host immune responses. Together our findings identify a new family of *Vibrio* effector proteins and highlight the role of horizontal gene transfer events among marine bacteria in shaping T3SS gene clusters.

**KEYWORDS** *Vibrio parahaemolyticus*, NleH, VPA1328, VopG, T3SS2, T3SS, type III secretion system, foodborne pathogen

*Vibrio parahaemolyticus* is a marine Gram-negative bacterium that is the leading bacterial cause of seafood-borne gastroenteritis worldwide (1). In 1996, a new clonal *V. parahaemolyticus* strain of the O3:K6 serotype, now known as the pandemic

**Citation** Plaza N, Urrutia IM, Garcia K, Waldor MK, Blondel CJ. 2021. Identification of a family of *Vibrio* type III secretion system effectors that contain a conserved serine/threonine kinase domain. *mSphere* 6:e00599-21. <https://doi.org/10.1128/mSphere.00599-21>.

**Editor** Alfredo G. Torres, UTMB

**Copyright** © 2021 Plaza et al. This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Address correspondence to C. J. Blondel, [carlos.blondel@unab.cl](mailto:carlos.blondel@unab.cl).

**Received** 1 July 2021

**Accepted** 22 July 2021

**Published** 4 August 2021

clone, emerged and has been responsible for major outbreaks of gastroenteritis in diverse locations around the globe (2).

In addition to the presence of the characterized virulence factors thermostable direct hemolysin (TDH) and the *tdh*-related hemolysin (TRH), genome sequencing revealed that all *V. parahaemolyticus* strains encode a type III secretion system on chromosome 1 (T3SS1) (3). Furthermore, strains related to the pandemic clone harbor an evolutionarily distinct T3SS known as T3SS2 (4–6) encoded within an 80-kb *V. parahaemolyticus* pathogenicity island 7 (VPal-7) on chromosome 2 (3). T3SSs are multicomponent nanomachines that enable Gram-negative bacteria to deliver proteins known as effectors directly from the bacterial cytosol into the cytosol of eukaryotic cells. Translocation of effectors into host cells enables pathogens to hijack host cell signaling, thereby manipulating a variety of host cell functions (reviewed in reference 7). Indeed, the virulence of many human, animal, and plant pathogens depends on the activity of the T3SS injectisome and the repertoire of effector proteins delivered to their respective hosts' cells (8, 9).


Notably, most *V. parahaemolyticus* strains isolated from human clinical samples harbor T3SS2, and studies of animal models have shown that T3SS2 is essential for *V. parahaemolyticus* to colonize the intestine and to cause enteritis and diarrhea (10–12). Therefore, T3SS2 is considered a key *V. parahaemolyticus* virulence factor. Several T3SS2-related gene clusters have been identified in other *Vibrio* species and are referred to as T3SS2 phylotypes (T3SS2 $\alpha$ , T3SS2 $\beta$ , and T3SS2 $\gamma$ ) (13). T3SS2 $\alpha$  include T3SS2 gene clusters related to those found in the *tdh*-positive *V. parahaemolyticus* pandemic strain RIMD2210633 and in *Vibrio cholerae* strain AM-19226. T3SS2 $\beta$  include T3SS2 gene clusters related to those found in *V. parahaemolyticus* strain TH3996 and *V. cholerae* strain 1587 (14). Finally, T3SS2 $\gamma$  include T3SS2 gene clusters related to those encoded in *V. parahaemolyticus* strain MAVP-Q, which has features found in the T3SS2 $\alpha$  and T3SS2 $\beta$  gene clusters (15).

Nine T3SS2 effector proteins in *V. parahaemolyticus* have been identified thus far (VopA, VopT, VopL, VopV, VopC, VopZ, VPA1380, VopO, and VgpA) (12, 16–23). These effectors subvert several cellular pathways, including those controlling actin cytoskeleton dynamics and innate inflammatory responses (reviewed in references 13, 24, 25). These effector proteins are classified as either core or accessory T3SS2 effector proteins based on their distribution among the T3SS2 phylotypes (13). Notably, the presence of multiple uncharacterized genes in the VPal-7 region raises the possibility that there are additional T3SS2 effector proteins yet to be identified.

In this study, we found that VPA1328, an open reading frame (ORF) in the *V. parahaemolyticus* VPal-7, encodes a novel T3SS2 effector protein. VPA1328, renamed here VopG, due to its similarity to the uncharacterized *V. cholerae* effector VopG, is secreted in a T3SS2-dependent fashion. Comparative genomic and phylogenetic analyses revealed that VPA1328 and VopG are members of a larger family of T3SS2 effector proteins encoded within the T3SS2 clusters of vibrios outside *V. parahaemolyticus* and *V. cholerae* including *Vibrio mimicus* and *Vibrio diabolicus* and the marine bacterium *Shewanella baltica*. The association of *vopG* genes with insertion sequence elements in several of these clusters suggests independent horizontal gene transfer or rearrangement events in these loci. Furthermore, VopG proteins have a conserved domain that exhibits sequence and predicted structural similarity to the serine/threonine kinase domain in the well-characterized NleH family of T3SS effector proteins. These effectors have been linked to subversion of host cell survival pathways and suppression of innate immunity in infected cells (26–28). However, VopG did not block host cell death or interleukin 8 (IL-8) secretion in tissue culture-based infections, suggesting a yet undefined role for VopG during infection or functional redundancy with other T3SS2 effector proteins.

## RESULTS

**VPA1328 is a VopG homolog that is secreted and translocated into host cells by the *Vibrio parahaemolyticus* T3SS2.** We carried out BLASTp-based homology searches of the *V. parahaemolyticus* VPal-7 genomic island as a way to identify candidate




**FIG 1** VPA1328, an ORF in the *V. parahaemolyticus* RIMD2210633 T3SS2 gene cluster, is similar to the VopG effector protein encoded within the *V. cholerae* AM-19226 T3SS2 gene cluster. (A) Schematic depiction of a comparison of the T3SS2 gene clusters in *V. parahaemolyticus* RIMD2210633 and *V. cholerae* AM-19226. BLASTn alignment was performed and visualized using Easyfig. (B) Multiple sequence alignment of VPA1328 and VopG homologs. BLASTp alignments were performed using T-Coffee Expresso and visualized using ESPrnt 3.0. Amino acids with a red background correspond to positions with 100% identity; amino acids with a yellow background correspond to positions with >70% identity.

new T3SS2 effector proteins. This approach suggested that VPA1328 (VP\_RS21530 in the latest genome annotation of strain RIMD2210633) is a putative T3SS2 effector protein (see Table S2 in the supplemental material). VPA1328 is predicted to encode a 260-amino-acid protein that shares ~42% amino acid sequence identity with the T3SS effector protein VopG, encoded in the phylogenetically related T3SS2 in *V. cholerae* AM-19226 (29) (Fig. 1A and B). The function of VopG remains unknown, but it is secreted and translocated by the *V. cholerae* T3SS2 and contributes to host cell cytotoxicity and colonization in a mouse model of infection (29), suggesting an important role for this effector in virulence (29). Even though VPA1328 and VopG are located in different locations within their respective T3SS2 clusters, their sequence similarity and presence in phylogenetically related T3SSs suggest that VPA1328 is a VopG homolog that functions as a *V. parahaemolyticus* T3SS2 effector protein. Below we refer to VPA1328 as VopG.

Next, we tested whether VopG (VPA1328) is secreted and whether its secretion requires the *V. parahaemolyticus* T3SS2. In these experiments, *V. parahaemolyticus* wild-type (WT) strain RIMD2210633 and isogenic T3SS1, T3SS2, and T3SS1/T3SS2-deficient mutant strains ( $\Delta vscn1$ ,  $\Delta vscn2$ , and  $\Delta vscn1 \Delta vscn2$ , respectively) were grown under conditions (26) that induce expression of T3SS2 (LB 0.04% bile) (30). To detect VopG, these strains were transformed with pVPA1328-CyaA, a plasmid that harbors a translational fusion between the VPA1328 ORF (VopG) and the adenylate cyclase domain (CyaA) of plasmid pCyaA. This construct enables immunoblot detection of VopG in cell lysates and culture supernatants using anti-CyaA antibodies. A VopG-CyaA fusion (pVopG-CyaA) was included as a positive control for T3SS2-dependent secretion (19).

A band corresponding to the predicted size of the VopG-CyaA fusion (~74 kDa, along with some lower-molecular-weight species likely corresponding to degradation products) was observed in cell lysates from the WT strain harboring pVopG-CyaA, but not a control strain harboring the empty vector pCyaA (Fig. 2A). VopG was detected




**FIG 2** VPA1328 is secreted and translocated in a T3SS2-dependent fashion. (A) Immunoblots of culture supernatants and whole-cell lysates using anti-CyaA antibodies for CyaA-tagged VPA1328 (VopG) and VPA1357 (VopV) in wild-type (WT) (A) and isogenic  $\Delta vscn1$ ,  $\Delta vscn2$ , and  $\Delta vscn1 \Delta vscn2$  mutant strains. Immunoblots for RpoB were used as a control for cell lysis. (B) Translocation of VopG-CyaA and VopV-CyaA fusions was assessed via determination of intracellular cAMP levels of infected Caco-2 cells. Values are means plus standard deviations (error bars) from two independent biological replicates each with four technical replicates. Asterisks indicate significant differences (*t* test, \*\*\*, *P* < 0.001). ns, not significantly different.

only in supernatants when the WT (pVopG-CyaA) strain was grown under T3SS2-inducing conditions (LB 0.04% bile) and not in culture supernatants in strains lacking a functional T3SS2 (Fig. 2A), suggesting that its secretion requires T3SS2 activity. Interestingly, previous transcriptomic analysis showed that expression of VPA1328 was increased by the presence of bile and controlled by VtrB, the master regulator of T3SS2 expression, suggesting that it is part of the VtrB regulon (31).

Analyses of VopG secretion from  $\Delta vscn1$  (T3SS1-deficient) and  $\Delta vscn2$  (T3SS2-deficient) strains strongly support the idea that VopG secretion requires T3SS2 and not T3SS1. When secretion by T3SS1 or T3SS2 or both T3SS was disabled by deletion of their respective ATPases, there was similar expression of VopG in cell lysates (Fig. 2A); however, VopG was detected only in supernatants from the strain where T3SS1 was inactivated but not when T3SS2 was inactive. An identical pattern was observed with VopV, a known T3SS2 substrate (Fig. 2A). The cytosolic RNA polymerase beta subunit (RpoB) was not detected in any of the culture supernatant samples, indicating that detection of VPA1328 in culture supernatants was not a consequence of bacterial lysis.

We also tested whether VPA1328 (VopG) is translocated into infected host cells by *V. parahaemolyticus* T3SS2. Caco-2 cells were infected with *V. parahaemolyticus* strains harboring the effector-CyaA reporter fusions described above, and the amount of intracellular cyclic AMP (cAMP) generated by each translocated effector was measured using an enzyme-linked immunosorbent assay (ELISA). As shown in Fig. 2B, after 1 h of infection, cAMP levels generated by VopV-CyaA (positive control) and VopG-CyaA were similar and significantly higher in cells infected with *V. parahaemolyticus* strains harboring a functional T3SS2 ( $\Delta vscn1$ , T3SS2+) than in cells infected with a T3SS-deficient strain ( $\Delta vscn1 \Delta vscn2$ , T3SS-), which exhibited background cAMP levels (Fig. 2B). Together, these observations demonstrate that VopG is secreted and translocated into host cells in a T3SS2-dependent fashion and given its similarity to the *V. cholerae* VopG effector, strongly support the notion that VopG is a novel *V. parahaemolyticus* T3SS2 effector protein.


**VopG homologs are widely distributed in vibrios harboring T3SS2 clusters.** The presence of a VopG homolog encoded within the T3SS2 gene cluster in *V. parahaemolyticus* RIMD2210633 prompted us to investigate whether additional VopG homologs are present among distinct T3SS2 phylotypes. The VPA1328 sequence was used as a query to identify potential VopG homologs by sequential BLASTn, BLASTp, and tBLASTx searches, using publicly available bacterial genome sequences. With cutoff values of 60% sequence



**FIG 3** VopG homologs are widely distributed among *Vibrio* and *Shewanella* species. (A) Number of *Vibrio* sp. and *Shewanella* sp. isolates where VopG homologs were identified. (B) Distribution of the 123 nonredundant VopG protein sequences in different *Vibrio* and *Shewanella* species. (C) Phylogenetic analysis of the 123 nonredundant VopG homologs identified in this study. Phylogenetic analysis was performed with MEGA and visualized by iTOL. Distinct bacterial species are highlighted in different colors. VopG homologs used in the multiple sequence alignment of Fig. 5A are highlighted with a black dot.

coverage and 40% sequence identity, 2,044 candidate VopG homologs were identified, including 123 nonredundant protein sequences (Fig. 3A and B and Table S3). The majority of the VopG homologs (86%;  $n = 1,764$ ) were encoded in *V. parahaemolyticus* strains and in *V. cholerae* strains (12.5%;  $n = 256$ ), but homologs were also identified in *V. mimicus* (0.2%;  $n = 5$ ), *V. diabolicus* (0.04%;  $n = 1$ ), and *Vibrio* sp. (0.5%;  $n = 11$ ) and in *Shewanella* strains (0.3%;  $n = 7$ ), i.e., in most species known to harbor T3SS2 gene clusters. Interestingly, a T3SS2 gene cluster was not previously identified in *V. diabolicus*, a marine organism. However, it is important to note that not all *Vibrio* species, e.g., *Vibrio anguillarum* (32) which harbors T3SS2 gene clusters, carry genes that encode VopG homologs. Thus, even though VopG is widely distributed, this putative effector protein is not a universal component of the T3SS2.

Next, we evaluated the sequence relatedness of VopG homologs using phylogenetic analysis of the 123 nonredundant VopG sequences. Three distinct clades (A, B, and C) of VopG proteins were identified (Fig. 3C), but no clear correlation was found between these clades and T3SS2 phylotypes. For example, the VopG homologs of *V. cholerae* strain AM-19226 and *V. parahaemolyticus* RIMD2210633 (VPA1328) clustered in different clades (B and A, respectively) despite the fact that both these T3SS2 belong to the T3SS2 $\alpha$  phylotype. The lack of correlation between the VopG clades and T3SS2



**FIG 4** Locations of *vopG* homologs within T3SS2 gene clusters. BLASTn alignments were performed and visualized using Easyfig.

phylotypes suggests that *VopG* effectors have to some extent evolved independently of the T3SS2 machinery that delivers them to host cells.

Comparative genomic analyses were carried out to gain insights into variation of the genomic contexts of *vopG* genes within different T3SS2 gene clusters. Genome sequences from representatives of each clade of the *VopG* phylogenetic tree, including at least one genome for each different *Vibrio* species were used for these comparisons. As shown in Fig. 4, the overall genetic structure of these T3SS2 gene clusters is highly conserved, particularly in the regions encoding structural components of the T3SS2 apparatus. In most T3SS2 gene clusters, the relative position of *vopG* was similar with the exception of *V. parahaemolyticus* RIMD2210633. However, the nucleotide sequences and ORFs that are adjacent to the *vopG* homologs differed in most of the seven clusters analyzed in Fig. 4. In several of these cases, *vopG* was found to be close to sequences related to insertion sequence (IS) elements. This association raises the possibility that IS elements can promote the mobility of *vopG* loci and potentially account for the variations in the genetic contexts of these loci within different T3SS2 gene clusters.

Consistent with this idea, we identified two *vopG* homologs (FORC14\_RS05860 and FORC14\_RS06170) encoded in the T3SS2 gene cluster of *V. parahaemolyticus* strain FORC014. Analysis of their respective genetic contexts revealed that one of these *vopG* genes (FORC14\_RS05860) is located at the end of the T3SS gene cluster and is flanked by IS200-like mobile genetic elements (see Fig. S1A in the supplemental material). These elements have high sequence identity to the ISVpa3 insertion sequence. ISVpa3 is an insertion sequence located adjacent to each copy of the TDH gene in *V. parahaemolyticus* strain RIMD2210633 and linked in some strains to deletion of TDH (33). While the T3SS2 gene cluster of *V. parahaemolyticus* RIMD2210633 has three copies of these ISVpa3 elements, *V. parahaemolyticus* strain FORC014 has six of these elements, two of them flanking one of the *vopG* homologs at the end of the cluster (Fig. S1B). Sequence analysis showed that the two *vopG* homologs in strain FORC014 share 69% nucleotide identity (Fig. S2). Both the sequence divergence of these two

*vopG* genes and the mobile genetic elements flanking FORC14\_RS05860 suggest that this *vopG* homolog was independently acquired, potentially via a horizontal gene transfer event, and not a duplication of FORC14\_RS06170.


While the presence of a T3SS2 gene cluster in *Shewanella baltica* species has been inferred due to the presence of the *vscn2* gene in strain *S. baltica* BA175 and *S. baltica* OS183 (34), information regarding the distribution and genetic context of the T3SS2 gene cluster in this genus has not been reported. We found that the *Shewanella* T3SS2 is located within a genomic island inserted between the SBAL678\_RS45345 and SBAL678\_RS45350 ORFs of reference strain OS678 (Fig. S1B). This genomic island includes 45 ORFs. Most of these genes encode structural components of the T3SS2 apparatus. Interestingly, not every T3SS2 gene cluster identified in *Shewanella* harbors a VopG-encoding gene (Fig. S1B).

**VopG proteins have sequence and predicted structural similarity to the NleH family of serine/threonine kinases.** The amino acid sequence conservation of the 123 VopG homologs was analyzed and depicted using WebLogo. The analysis showed a particularly striking conservation in the C termini of these amino acid sequences (Fig. S3), suggesting that this region of VopG includes a functional domain. To gain clues regarding the function of VopG proteins, we used the structure-based homology tools HHpred (35) and pGenTHREADER (36). For these analyses, the amino acid sequence of *V. parahaemolyticus* VPA1328 was used as a representative of the VopG family of effectors. Both algorithms detected a region in the VopG C terminus with similarity to NleH effectors, e.g., HHpred analysis uncovered the presence of a region of 22 amino acids in VPA1328 (positions 190 to 212) with identity to the T3SS effector proteins NleH1 from *Escherichia coli* O157:H7 strain Sakai (PDB accession no. 4LRJ chain B) and OspG from *Shigella flexneri* 2a strain 301 (PDB accession no. 4Q5E chain A).

NleH1 and OspG are members of the NleH family of T3SS effectors (37–39). These proteins are translocated by the T3SSs of different bacterial species and act as serine/threonine kinases in host cells (38). There are six members of this family of effector proteins, including the NleH1 and NleH2 proteins of *E. coli* O157:H7 strain Sakai, OspG from *Shigella flexneri* 2a strain 301, NleH of *Citrobacter rodentium* strain DBS100, SboH of *Salmonella bongori* NCTC 12419, and YspK of *Yersinia enterocolitica* strain 8081 (26, 28, 40–43). The serine/threonine kinase domain of these effectors is distantly related to eukaryotic regulatory kinases; moreover, functional studies have suggested that these effectors can perturb the NF- $\kappa$ B pathway, interfere with innate immune responses, and inhibit apoptosis in infected host cells (26–28).

Multiple sequence alignment of representatives of the NleH and VopG family of T3SS effector proteins were carried out to gain further insight into their similarity. Representatives from each clade of VopG proteins were included in these analyses. The analysis showed that the greatest similarity between VopG and NleH proteins is found in their C termini in the region that includes the characterized NleH serine/threonine kinase domain; in contrast, their N termini differ in both length and sequence (Fig. 5A and Fig. S4). VopG proteins contain all the critical amino acid residues and motifs important for kinase activity, including the conserved catalytic residues glycine of the G-rich loop, the aspartic acid (D) and the asparagine (N) of the catalytic loop (alignment positions 200 to 205 in VPA1328) and the PID motif of the activation loop (alignment positions 220 to 233 in VPA1328). In addition, VopG proteins also share the invariant lysine (alignment position 109) involved in the autophosphorylation of the NleH family, and which has been used as a proxy to measure kinase activity (27) (Fig. 5A and B). Thus, VopG family effector proteins harbor a NleH-like C-terminal serine/threonine kinase domain. Phylogenetic analysis of bacterial serine/threonine kinase domains also revealed the similarity of the kinase domains of VopG and NleH proteins (Fig. 6A). The VopG proteins clustered closer to the NleH proteins on this tree than to non-NleH serine/threonine kinases from *Legionella pneumophila*, *Yersinia pestis*, and *Salmonella enterica*.

We derived a three-dimensional (3D) structural model of the C-terminal domain of VPA1328 using comparative homology modeling with I-TASSER (44) to gain further insight into the serine/threonine kinase domain of VopG proteins. In accord with the




**FIG 5** Conservation of the C-terminal domains of VopG homologs. (A) Multiple sequence alignment and WebLogo analysis of the C-terminal domains of VopG proteins (amino acids 84 to 260 in VPA1328) with the serine/threonine kinase domains of NleH proteins. The G-rich loop and catalytic and activation loops of the kinase are highlighted in colored boxes matching the schematic diagram in panel B. BLASTp alignment was performed using T-Coffee Expresso and visualized by ESPrnt 3.0. Amino acids within a red background correspond to positions with 100% identity; amino acids with a yellow background correspond to positions with >70% identity. The secondary structure of NleH1 and OspG is shown flanking the alignment ( $\alpha$ , alpha helices;  $\beta$ , beta sheets; T, turns). (B) Schematic representation of VPA1328 highlighting the presence of the T3S signal as well as conserved regions and key catalytic residues of the putative serine/threonine kinase domain identified in panel A.

HHPred and pGenTHREADER analyses, I-TASSER identified NleH1, NleH2, and OspG as suitable models for comparative homology models using the crystal structures available for these proteins. Five models were obtained, and I-TASSER model 1 was chosen based on its error estimation, template modeling score (TM-score) and root mean square deviation (RMSD) values (Fig. S5). As shown in Fig. 6B, this model revealed the remarkable similarity of the predicted structure of the VPA1328 kinase domain with the NleH kinase domain. The structure of the catalytic pocket, including the positions of the predicted catalytic amino acid side chains (K109, D201, and N205) in VPA1328 and OspG structure overlap (Fig. 6B), strongly supporting the notion that the VopG family of proteins encode a NleH-like serine/threonine kinase domain.

**VopG does not modulate T3SS2-mediated cytotoxicity or inhibit IL-8 production.**


NleH family effector proteins inhibit IL-8 expression (26) and host cell death during infection (26–28). Since *V. parahaemolyticus* capacity to suppress IL-8 secretion and to induce host cell death is partially dependent on a functional T3SS2 (19, 45), we evaluated whether VopG contributes to these processes. A *V. parahaemolyticus* mutant strain harboring a deletion of *vopG* in the  $\Delta vscn1$  genetic background was constructed to assess whether *vopG* modulates T3SS2-dependent killing of intestinal Caco-2 cells. As expected, Caco-2 cells were killed (<50% survival within 3.5 h of infection) by a *V. parahaemolyticus*





**FIG 6** VopG homologs contain a NleH-like serine/threonine kinase domain. (A) Phylogenetic analysis of bacterial serine/threonine kinases. The analysis was performed with MEGA and visualized by iTOL. PKA, protein kinase A. (B) Comparative homology model of the C-terminal domain of VPA1328 (amino acids 84 to 260) superimposed on the known structure OspG (PDB accession no. 4BVU). The inset depicts the catalytic domain of OspG and the superimposed predicted structure of this region in VPA1328. Homology modeling was performed using the I-TASSER pipeline and visualized with MAESTRO.

strain harboring a functional T3SS2 ( $\Delta vscn1$ , T3SS2+), whereas cells infected with a *V. parahaemolyticus* strain lacking both T3SSs ( $\Delta vscn1 \Delta vscn2$ ) were not (Fig. 7A). However, the absence of *vopG* ( $\Delta vscn1 \Delta vopG$ , T3SS2+) did not alter survival of host cells infected with a functional T3SS2 (overlap of red and orange survival curves in Fig. 7A), suggesting that *vopG* does not modulate T3SS2-dependent cytotoxicity.



**FIG 7** VopG does not modulate T3SS2-dependent cytotoxicity or suppression of IL-8 production. (A) Survival kinetics of Caco-2 cells infected with WT *V. parahaemolyticus* or derivatives with inactive T3SS1 ( $\Delta vscn1$ ), inactive T3SS1 without *vopG* ( $\Delta vscn1$ ,  $\Delta vopG$ ), or inactive T3SS1 and T3SS2 ( $\Delta vscn1$ ,  $\Delta vscn2$ ). Cell viability was evaluated by trypan blue exclusion tests at the indicated times. (B) Levels of IL-8 secretion (in picograms per milliliter) from HeLa cells infected with the indicated *V. parahaemolyticus* strains in the presence or absence of IL-1 $\beta$  (25 ng/ml) as an inducer. Error bars indicate standard deviations from two biological replicates each with two technical replicates. Asterisks indicate significant differences (multiple paired *t* test,  $P < 0.001$ ) in comparison to the respective infected cells without IL-1 $\beta$  induction.

We then tested whether VopG contributes to T3SS2-dependent suppression of IL-8 production in infected cells. HeLa cells were infected with *V. parahaemolyticus* strains for 1.5 or 3.5 h and then IL-8 secretion was stimulated by incubating the cells with IL-1 $\beta$  for 90 min, as previously described (19). Infection by *V. parahaemolyticus* inhibited IL-8 secretion in a T3SS2-dependent fashion, but the absence of *vopG* did not influence this phenotype (Fig. 7B). Together, these data suggest that VopG does not modulate T3SS2-dependent host cell death or inhibit IL-8 production in infected cells.

## DISCUSSION

While all *Vibrio parahaemolyticus* strains harbor T3SS1, a hallmark of the pandemic *V. parahaemolyticus* O3:K6 clone and most human clinical *V. parahaemolyticus* isolates, is the presence of a second and phylogenetically distinct T3SS2. The latter T3SS is essential for both intestinal colonization and virulence in some animal models of disease (10, 12). Here, we found that a T3SS2 ORF (VPA1328) likely corresponds to a novel *V. parahaemolyticus* T3SS2 effector protein. This ORF, which is secreted in a T3SS2-dependent fashion, bears similarity to the VopG effector found in the *V. cholerae* AM-19226 T3SS2. The function of the latter VopG protein is unknown, but it has been shown to be translocated to host cells and linked to *V. cholerae* AM-19226's pathogenicity. Bioinformatic analyses uncovered 123 nonredundant VopG-like proteins encoded in all three phylotypes of T3SS2 clusters in diverse *Vibrio* species and in *Shewanella baltica*. Interestingly, the evolutionary history of the T3SS2 phylotypes does not appear to correspond with the evolution of the three clades of VopG proteins that were uncovered by phylogenetic analysis. We found that the highly conserved C-terminal domains of VopG proteins bear striking structural similarity to the serine/threonine kinase domain of the NleH family of effectors found in enteric pathogens such as EHEC and *Shigella* (OspG). Thus, our findings support the idea that VopG effectors function as serine/threonine kinases in host cells.

The *V. cholerae* AM-19226 effector VopG had been classified as a *V. cholerae*-specific T3SS effector (29, 46), but our analyses showed that VopG homologs belong to a larger family of putative effector proteins that is widely distributed among *Vibrio* species, including *V. parahaemolyticus*, *V. cholerae*, *V. mimicus*, and *V. diabolis* as well as in strains of *S. baltica*. Recently, Matsuda et al. (13) proposed classifying T3SS2 effectors proteins as "core" effectors if they are conserved in both *V. parahaemolyticus* and non-O1/non-O139 *V. cholerae* and as "accessory" effectors if they are not. According to this classification, our work suggests that VopG corresponds to a core effector protein due

to its presence in multiple *Vibrio* species. However, VopG homologs are not present in the T3SS2 gene clusters identified in all *Vibrio* species; e.g., the T3SS2 cluster in *Vibrio anguillarum* (32) lacks a VopG homolog and not all clusters in *V. mimicus* (47) encode a recognizable VopG.

T3SS2 gene clusters are classified into three phlotypes (T3SS2 $\alpha$ , T3SS2 $\beta$ , and T3SS2 $\gamma$ ) that are believed to have been acquired through horizontal gene transfer events (13, 15, 47). Even though VopG homologs are not universally found in all T3SS2 gene clusters, we identified VopG homologs in all three T3SS2 phlotypes. Phylogenetic analysis identified three distinct VopG clades (Fig. 3C). These VopG clades did not correlate with T3SS2 phlotypes, i.e., all three clades were found in each T3SS2 phlyotype. The apparent independent evolution of T3SS2 phlotypes and VopG clades supports the possibility that *vopG* genes have been independently acquired by different T3SS2 lineages.

The absence of *vopG* genes from certain T3SS2 clusters could be explained either by loss of *vopG* loci due to deletion event(s) or independent acquisition of *vopG* in some T3SS2 clusters. The presence of a second *vopG* homolog flanked by IS elements in *V. parahaemolyticus* strain FORC014 suggests insertion sequences may play a role in mobilizing *vopG* genes. These sequences bear similarity to the ISVpa3 insertion sequence first reported in *V. parahaemolyticus* RIMD2210633 (33). Since insertion sequences have been shown to shape bacterial genomic islands through rearrangements, insertion, and deletion events, it is plausible that ISVpa3-like elements have shaped the evolution of T3SS2 gene clusters through similar mechanisms. The apparent mobility of *vopG* loci adds an additional layer of complexity to our understanding of T3SS2 clusters. That is, these clusters appear to have been spread via horizontal gene transfer events among marine bacteria, and their repertoire of effector proteins appears to be “tunable” through independent horizontal gene transfer or rearrangement events.

Analysis of the amino acid sequences of the 123 nonredundant VopG homologs identified here revealed a particularly high degree of conservation in their C termini. This region of VopG proteins was found to be very similar to the conserved serine/threonine kinase domain in the NleH family of T3SS effector proteins. Thus, the conservation of this part of VopG effectors is likely explained by the presence of a functional kinase domain. Structural predictions, which showed that VopG proteins contain all the residues that constitute that catalytic pocket of NleH proteins, strongly support this hypothesis.

The NleH family of effectors contain a eukaryotic-like serine/threonine kinase domain that independently evolved in bacteria (37, 38). VopG homologs harbor each of the key residues described in the NleH family of protein kinases. The classification of the NleH proteins as a distinct bacterial kinase family was made through structure-based phylogenetic analysis (37). Phylogenetic analysis showed that the C termini of VopG proteins have more similarity to the kinase domain of NleH proteins than to other bacterial protein kinases (Fig. 6A), but further structural information is required to determine whether VopG proteins are novel members of the NleH family or represent a distinct family on their own.

Although the conservation of key catalytic residues in VopG and NleH proteins provides evidence that supports the notion that VopG proteins are functional serine/threonine kinases, it is more problematic to speculate that their biological function is conserved as well. To date, NleH proteins have been shown to perturb the NF- $\kappa$ B pathway and impact cell survival and innate immune responses during infection through different molecular mechanisms (26–28, 40, 48). Both NleH1 and NleH2 proteins bind the host protein RPS3 leading to inhibition or activation of the NF- $\kappa$ B pathway, respectively (26, 49), but only NleH1 suppresses IL-8 expression during EHEC infection (26). Despite these differences in control of IL-8 expression, both NleH1 and NleH2 inhibit apoptosis through interaction with the Bax inhibitor 1 protein (27). The *Shigella* OspG protein inhibits the NF- $\kappa$ B pathway by inhibiting the proteasomal destruction of I $\kappa$ B $\alpha$  (42), and the SboH protein of *Salmonella bongori* blocks intrinsic apoptotic pathways (28). The *V. parahaemolyticus* T3SS2 causes cell death (18, 50, 51) and suppresses IL-8

secretion through perturbation of the NF- $\kappa$ B pathway (19, 45). While the exact mechanism of T3SS2-mediated host cell death is unknown, the VopZ effector protein plays an important role in inhibiting IL-8 production (19). Our tissue culture-based infection experiments did not reveal that VopG modulates T3SS2-dependent host cell death or IL-8 suppression (Fig. 7). Two possible scenarios might explain these observations. (i) VopG's contribution to these phenotypes are masked by the redundant effects of additional effectors such as VopZ. (ii) VopG targets host pathways that do not influence cell death or IL-8 synthesis. The N-terminal region of NleH proteins has been linked to substrate recognition and the observed functional differences between the NleH1 and NleH2 proteins (26, 37, 40). In this context, it is tempting to speculate that the sequence divergence observed within the N-terminal region of VopG homologs (see Fig. S3 and S4 in the supplemental material) has functional implications.

In summary, our work identifies a new family of VopG proteins that are likely T3SS2 effectors. These proteins contain a distinctive NleH-like serine/threonine kinase domain. Future biochemical and structural studies are required to corroborate these predictions. Moreover, defining the role(s) of these effectors in the pathogenicity and/or environmental adaptation of the diverse *Vibrio* and *Shewanella* species that encode them will be fruitful.

## MATERIALS AND METHODS

**Bacterial strains and growth conditions.** All bacterial strains and plasmids used in this study are listed in Table S1 in the supplemental material. *V. parahaemolyticus* RIMD2210633 (3) and its  $\Delta vscn1$ ,  $\Delta vscn2$ , and  $\Delta vscn1 \Delta vscn2$  derivatives (19) were used in this study. Bacterial strains were routinely cultured in LB medium or on LB agar plates at 37°C. Culture medium was supplemented with the following antibiotics and chemicals: 0.04% bovine and ovine bile (Sigma catalog no. B8381); 5  $\mu$ g/ml and 20  $\mu$ g/ml chloramphenicol for *V. parahaemolyticus* and *E. coli* strains, respectively; 1 mM isopropyl- $\beta$ -D-thiogalactopyranoside (IPTG) to induce expression vector pCyaA in secretion and translocation assays.

**Eukaryotic cell culture and maintenance conditions.** Caco-2 cells (ATCC HTB-37) were maintained in Dulbecco's modified Eagle medium (DMEM) (Gibco) supplemented with 10% fetal bovine serum (FBS) (Gibco) (DMEM+15% FBS) at 37°C in 5% CO<sub>2</sub>. Cells were grown at 37°C with 5% CO<sub>2</sub> and routinely passaged at 70 to 80% confluence.

**T3SS2 secretion assays.** A reporter fusion was constructed between VPA1328 and the CyaA reporter encoded in plasmid pCyaA (a pMMB207 derivative) (19), generating plasmid pVPA1328 (VopG-CyaA), to investigate VPA1328 (VopG) secretion. A VopV-CyaA fusion (pVopV-CyaA) (19) was used as a positive control for T3SS2-dependent secretion, and the empty plasmid pCyaA was used as a negative control. Each plasmid was transformed into *V. parahaemolyticus* by electroporation as previously described (19). Secretion assays were performed by growing each *V. parahaemolyticus* strain for 1.5 h in LB medium supplemented with 0.04% bile. When cultures reached an optical density at 600 nm (OD<sub>600</sub>) of 0.5 to 0.6, 1 mM IPTG was added to induce expression of the CyaA reporter fusion protein. After 1.5 h of induction, culture supernatants were collected by two centrifugations, one at 5,000 rpm for 20 min and a final centrifugation at 13,000 rpm for 5 min. The supernatants were then filter sterilized through a 0.22- $\mu$ m filter and concentrated 100-fold by repeated centrifugation at 5,000 rpm for 30 min with an Amicon Ultra-15 centrifugal filter unit (Millipore) with a 10-kDa molecular weight cutoff and with two washes with 15 ml of 1 $\times$  phosphate-buffered saline (PBS) as an exchange buffer. Prior to concentrating the culture supernatant, bovine serum albumin (BSA) (1 mg/ml) was added to serve as a concentration/loading control. Whole-cell lysates were prepared by solubilizing the bacterial pellets in 1 $\times$  Laemmli buffer. Lysate and supernatant samples were processed for sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) analysis by mixing them with loading buffer and boiling for 5 min; they were then run on 4 to 20% Mini-PROTEAN TGX Precast Gels (Bio-Rad) per 30 min at 200 V. For immunoblot analysis, gels were transferred to iBlot2 transfer stacks of polyvinylidene difluoride (PVDF) membranes (Invitrogen) and blocked by EveryBlot blocking buffer (Bio-Rad catalog no. 12010020). The Pierce Coomassie Plus (Bradford) assay kit (Thermo Fisher catalog no. 23236) was used for determination of protein concentrations. Antibodies were used at the following dilutions: anti-CyaA (mouse monoclonal, 1:2,000; Santa Cruz Biotechnology catalog no. sc-13582), anti-RpoB (rabbit monoclonal, 1:2,000; Abcam catalog no. ab191598), anti-mouse IgG conjugated to horseradish peroxidase (HRP) (anti-mouse IgG-HRP) (goat polyclonal 1:10,000; Thermo catalog no. 62-6520), and anti-rabbit IgG (H+L) secondary antibody conjugated to HRP (goat polyclonal 1:10,000; Invitrogen catalog no. G21234). The blots were developed with SuperSignal West Pico Plus substrate (Thermo Fisher catalog no. 35060), and imaging was performed on a C-DiGit Blot Scanner (LI-COR Biosciences). All blots are representative of at least three biological replicates.

**Translocation of effector-CyaA fusion proteins.** CyaA reporter fusion-based protein translocation assays were performed as previously described (18). Briefly, Caco-2 cells were seeded at 1.5  $\times$  10<sup>4</sup> cells/well and cultured in DMEM+10% FBS for 2 days in a 96-well plate at 37°C in 5% CO<sub>2</sub>. *V. parahaemolyticus* RIMD2210633  $\Delta vscn1$  and  $\Delta vscn1 \Delta vscn2$  strains containing pCyaA, pVopV-CyaA or pVopG-CyaA were grown for 1.5 to 2 h until they reached an OD<sub>600</sub> of 0.6 in LB medium supplemented with 0.04% bile. The

infection assay in Caco-2 cells was performed for 1 h at 37°C and 5% CO<sub>2</sub> and at a multiplicity of infection (MOI) of 50. The intracellular cyclic AMP (cAMP) levels in Caco-2 cells were determined using cAMP Biotrak enzyme immunoassay (EIA) kit (Cytiva catalog no. RPN2251) as described previously (52). Statistical analysis was performed with GraphPad Prism version 9 (GraphPad Software, San Diego, California, USA).

**T3SS2-dependent cell death and IL-8 secretion assays.** For cell survival assays, Caco-2 cells were seeded at  $8.0 \times 10^4$  cells/well into six-well plates and grown for 2 days in complete media. *V. parahaemolyticus* strains were cultured overnight and the next day diluted 1:100 into LB liquid media containing 0.04% bile (to induce T3SS2 expression) and grown for 2 h until attaining an OD<sub>600</sub> of 0.6. Cells were infected at an MOI of 1 and incubated at 37°C with 5% CO<sub>2</sub>. At each time point assayed (0.5, 1.0, 1.5, 2.5, and 3.5 h), the medium was replaced with fresh complete DMEM medium supplemented with 100 µg/ml of gentamicin. Cells were incubated overnight, and surviving cells were quantified either by trypan blue exclusion (0.4% trypan blue) and counted on a hemocytometer (Neubauer cell chamber). For the detection of secreted IL-8, Caco-2 cells were seeded at  $1.0 \times 10^5$  cells/well into 12-well plates and cultured in DMEM–10% FBS for 24 h at 37°C in 5% CO<sub>2</sub>. *V. parahaemolyticus* strains were cultured, and T3SS2 was induced as described above. Cells were infected at an MOI of 1 and incubated at 37°C with 5% CO<sub>2</sub> for 1.5 or 3.5 h, and then, the infection was terminated by addition of gentamicin (100 µg/ml). In parallel with gentamicin, the cells were treated with IL-1β (25 ng/ml) or left untreated for 90 min. IL-8 in culture supernatant was then measured using a human IL-8 ELISA kit (ab46032). Statistical analysis was performed with GraphPad Prism version 9 (GraphPad Software, San Diego, California, USA).

**Sequence and phylogenetic analysis.** Identification of VopG orthologs was carried out using the VPA1328 amino acid and nucleotide sequences as queries in BLASTp, BLASTn, BLASTx, tBLASTn, and tBLASTx analyses (64) using publicly available bacterial genome sequences of the NCBI database (December 2020). A 94% sequence length, 40% identity and 60% sequence coverage threshold were used to select positive matches. Sequence conservation was analyzed by multiple sequence alignments using MAFFT (53) and T-Coffee Expresso (54) and visualized by ESPrnt 3.0 (55). WebLogo analysis was performed using multiple sequence alignments (56). Comparative genomic analysis of the T3SS2 gene clusters was performed using the multiple aligner Mauve (57) and the IslandViewer 4 pipeline (58) and EasyFig v2.2.2 (65). Nucleotide sequences were analyzed by the sequence visualization and annotation tool Artemis version 18.1 (59). Multiple sequence alignments were used for phylogenetic analyses that were performed with the Molecular Evolutionary Genetics Analysis (MEGA) software version 7.0 (60) and visualized by iTOL (61). Phylogenetic trees were built from the alignments by the bootstrap test of phylogeny (2000 replications) using the maximum-likelihood (ML) method with a Jones-Taylor-Thornton (JTT) correction model.

**Remote homology prediction and homology modeling.** Remote homology prediction of VPA1328 was performed using HHpred (35) and pGENTHREADER (36) on the PSIPRED server (62). Protein structure models of the VPA1328 C-terminal domain were obtained using I-TASSER (44), a protein structure homology-modeling server. Protein structure visualization and template alignment and superposition were performed using MAESTRO (63).

## SUPPLEMENTAL MATERIAL

Supplemental material is available online only.

**FIG S1**, PDF file, 0.8 MB.

**FIG S2**, PDF file, 0.9 MB.

**FIG S3**, PDF file, 0.3 MB.

**FIG S4**, PDF file, 1.1 MB.

**FIG S5**, PDF file, 0.2 MB.

**TABLE S1**, XLSX file, 0.01 MB.

**TABLE S2**, XLSX file, 0.01 MB.

**TABLE S3**, XLSX file, 0.1 MB.

## ACKNOWLEDGMENTS

We thank members of the Blondel Laboratory for helpful discussions on all aspects of this project and for their comments on the manuscript.

This work was funded by the Howard Hughes Medical Institute (HHMI)-Gulbenkian International Research Scholar grant 55008749, FONDECYT grant 1201805 (ANID) and REDI170269 (ANID) to C.J.B. I.M.U. is supported by FONDECYT grant 3200874 (ANID). K.G. is supported by FONDECYT grant 1190957 (ANID). M.K.W. is a Howard Hughes Medical Institute (HHMI) Investigator and is supported by NIAID grant R01-AI-043247.

N. Plaza: Conceptualization, Methodology, Formal analysis, Investigation, Visualization, Data curation, Writing - Original Draft and review and editing. I. M. Urrutia: Investigation, Visualization, review and editing final manuscript. K. Garcia: Conceptualization, review and editing final manuscript. M. K. Waldor: Conceptualization, Resources, Writing - Review and editing. C. J. Blondel: Conceptualization, Methodology, Formal analysis, Investigation,

Visualization, Resources, Data curation, Writing - Review and editing, Funding acquisition, Supervision and Project administration.

We declare that we have no conflicts of interest.

## REFERENCES

- Letchumanan V, Chan K-G, Lee L-H. 2014. *Vibrio parahaemolyticus*: a review on the pathogenesis, prevalence, and advance molecular identification techniques. *Front Microbiol* 5:705. <https://doi.org/10.3389/fmicb.2014.00705>.
- Velazquez-Roman J, León-Sicairens N, de Jesus Hernández-Díaz L, Canizalez-Roman A. 2014. Pandemic *Vibrio parahaemolyticus* O3:K6 on the American continent. *Front Cell Infect Microbiol* 3:110. <https://doi.org/10.3389/fcimb.2013.00110>.
- Makino K, Oshima K, Kurokawa K, Yokoyama K, Uda T, Tagomori K, Iijima Y, Najima M, Nakano M, Yamashita A, Kubota Y, Kimura S, Yasunaga T, Honda T, Shinagawa H, Hattori M, Iida T. 2003. Genome sequence of *Vibrio parahaemolyticus*: a pathogenic mechanism distinct from that of *V. cholerae*. *Lancet* 361:743–749. [https://doi.org/10.1016/S0140-6736\(03\)12659-1](https://doi.org/10.1016/S0140-6736(03)12659-1).
- Hazen TH, Lafon PC, Garrett NM, Lowe TM, Silberger DJ, Rowe LA, Ftrace M, Parsons MB, Bopp CA, Rasko DA, Sobocky PA. 2015. Insights into the environmental reservoir of pathogenic *Vibrio parahaemolyticus* using comparative genomics. *Front Microbiol* 6:204. <https://doi.org/10.3389/fmicb.2015.00204>.
- Abby SS, Rocha EPC. 2012. The non-flagellar type III secretion system evolved from the bacterial flagellum and diversified into host-cell adapted systems. *PLoS Genet* 8:e1002983. <https://doi.org/10.1371/journal.pgen.1002983>.
- Park K-S, Ono T, Rokuda M, Jang M-H, Okada K, Iida T, Honda T. 2004. Functional characterization of two type III secretion systems of *Vibrio parahaemolyticus*. *Infect Immun* 72:6659–6665. <https://doi.org/10.1128/IAI.72.11.6659-6665.2004>.
- Portaliou AG, Tsohis KC, Loos MS, Zorzini V, Economou A. 2016. Type III secretion: building and operating a remarkable nanomachine. *Trends Biochem Sci* 41:175–189. <https://doi.org/10.1016/j.tibs.2015.09.005>.
- Lara-Tejero M, Galán JE. 2019. The injectisome, a complex nanomachine for protein injection into mammalian cells. *EcoSal Plus* 8:10.1128/ecosalplus.ESP-0039-2018. <https://doi.org/10.1128/ecosalplus.ESP-0039-2018>.
- Galán JE, Lara-Tejero M, Marlovits TC, Wagner S. 2014. Bacterial type III secretion systems: specialized nanomachines for protein delivery into target cells. *Annu Rev Microbiol* 68:415–424. <https://doi.org/10.1146/annurev-micro-092412-155725>.
- Hubbard TP, Chao MC, Abel S, Blondel CJ, Wiesch PAZ, Zhou X, Davis BM, Waldor MK. 2016. Genetic analysis of *Vibrio parahaemolyticus* intestinal colonization. *Proc Natl Acad Sci U S A* 113:6283–6288. <https://doi.org/10.1073/pnas.1601718113>.
- Piñeyro P, Zhou X, Orfe LH, Friel PJ, Lahmers K, Call DR. 2010. Development of two animal models to study the function of *Vibrio parahaemolyticus* type III secretion systems. *Infect Immun* 78:4551–4559. <https://doi.org/10.1128/IAI.00461-10>.
- Ritchie JM, Rui H, Zhou X, Iida T, Kodama T, Ito S, Davis BM, Bronson RT, Waldor MK. 2012. Inflammation and disintegration of intestinal villi in an experimental model for *Vibrio parahaemolyticus*-induced diarrhea. *PLoS Pathog* 8:e1002593. <https://doi.org/10.1371/journal.ppat.1002593>.
- Matsuda S, Hiyoshi H, Tandhavanant S, Kodama T. 2020. Advances on *Vibrio parahaemolyticus* research in the postgenomic era. *Microbiol Immunol* 64:167–181. <https://doi.org/10.1111/1348-0421.12767>.
- Okada N, Iida T, Park K-S, Goto N, Yasunaga T, Hiyoshi H, Matsuda S, Kodama T, Honda T. 2009. Identification and characterization of a novel type III secretion system in trh-positive *Vibrio parahaemolyticus* strain TH3996 reveal genetic lineage and diversity of pathogenic machinery beyond the species level. *Infect Immun* 77:904–913. <https://doi.org/10.1128/IAI.01184-08>.
- Xu F, Gonzalez-Escalona N, Drees KP, Sebra RP, Cooper VS, Jones SH, Whistler CA. 2017. Parallel evolution of two clades of an Atlantic-endemic pathogenic lineage of *Vibrio parahaemolyticus* by independent acquisition of related pathogenicity islands. *Appl Environ Microbiol* 83:e01168-17. <https://doi.org/10.1128/AEM.01168-17>.
- Hiyoshi H, Okada R, Matsuda S, Gotoh K, Akeda Y, Iida T, Kodama T. 2015. Interaction between the type III effector VopO and GEF-H1 activates the RhoA-ROCK pathway. *PLoS Pathog* 11:e1004694. <https://doi.org/10.1371/journal.ppat.1004694>.
- Hiyoshi H, Kodama T, Saito K, Gotoh K, Matsuda S, Akeda Y, Honda T, Iida T. 2011. VopV, an F-actin-binding type III secretion effector, is required for *Vibrio parahaemolyticus*-induced enterotoxicity. *Cell Host Microbe* 10:401–409. <https://doi.org/10.1016/j.chom.2011.08.014>.
- Kodama T, Rokuda M, Park K-S, Cantarelli VV, Matsuda S, Iida T, Honda T. 2007. Identification and characterization of VopT, a novel ADP-ribosyltransferase effector protein secreted via the *Vibrio parahaemolyticus* type III secretion system 2. *Cell Microbiol* 9:2598–2609. <https://doi.org/10.1111/j.1462-5822.2007.00980.x>.
- Zhou X, Gewurz BE, Ritchie JM, Takasaki K, Greenfeld H, Kieff E, Davis BM, Waldor MK. 2013. A *Vibrio parahaemolyticus* T3SS effector mediates pathogenesis by independently enabling intestinal colonization and inhibiting TAK1 activation. *Cell Rep* 3:1690–1702. <https://doi.org/10.1016/j.celrep.2013.03.039>.
- Zhang L, Krachler AM, Broberg CA, Li Y, Mirzaei H, Gilpin CJ, Orth K. 2012. Type III effector VopC mediates invasion for *Vibrio* species. *Cell Rep* 1:453–460. <https://doi.org/10.1016/j.celrep.2012.04.004>.
- Trosky JE, Mukherjee S, Burdette DL, Roberts M, McCarter L, Siegel RM, Orth K. 2004. Inhibition of MAPK signaling pathways by VopA from *Vibrio parahaemolyticus*. *J Biol Chem* 279:51953–51957. <https://doi.org/10.1074/jbc.M407001200>.
- Tandhavanant S, Matsuda S, Hiyoshi H, Iida T, Kodama T. 2018. *Vibrio parahaemolyticus* senses intracellular K<sup>+</sup> to translocate type III secretion system 2 effectors effectively. *mBio* 9:e01366-18. <https://doi.org/10.1128/mBio.01366-18>.
- Hu M, Zhang Y, Gu D, Chen X, Waldor MK, Zhou X. 2021. Nucleolar c-Myc recruitment by a *Vibrio* T3SS effector promotes host cell proliferation and bacterial virulence. *EMBO J* 40:e105699. <https://doi.org/10.15252/embj.2020105699>.
- Lingzhi L, Meng H, Dan G, Yang L, Mengdie J. 2019. Molecular mechanisms of *Vibrio parahaemolyticus* pathogenesis. *Microbiol Res* 222:43–51. <https://doi.org/10.1016/j.micres.2019.03.003>.
- O'Boyle N, Boyd A. 2014. Manipulation of intestinal epithelial cell function by the cell contact-dependent type III secretion systems of *Vibrio parahaemolyticus*. *Front Cell Infect Microbiol* 3:114. <https://doi.org/10.3389/fcimb.2013.00114>.
- Gao X, Wan F, Mateo K, Callegari E, Wang D, Deng W, Puente J, Li F, Chaussee MS, Finlay BB, Lenardo MJ, Hardwidge PR. 2009. Bacterial effector binding to ribosomal protein S3 subverts NF- $\kappa$ B function. *PLoS Pathog* 5:e1000708. <https://doi.org/10.1371/journal.ppat.1000708>.
- Hemrajani C, Berger CN, Robinson KS, Marchès O, Mousnier A, Frankel G. 2010. NleH effectors interact with Bax inhibitor-1 to block apoptosis during enteropathogenic *Escherichia coli* infection. *Proc Natl Acad Sci U S A* 107:3129–3134. <https://doi.org/10.1073/pnas.0911609106>.
- Fookes M, Schroeder GN, Langridge GC, Blondel CJ, Mammina C, Connor TR, Seth-Smith H, Vernikos GS, Robinson KS, Sanders M, Petty NK, Kingsley RA, Bäuml AJ, Nuccio S-P, Contreras I, Santiviago CA, Maskell D, Barrow P, Humphrey T, Nastasi A, Roberts M, Frankel G, Parkhill J, Dougan G, Thomson NR. 2011. *Salmonella bongori* provides insights into the evolution of the Salmonellae. *PLoS Pathog* 7:e1002191. <https://doi.org/10.1371/journal.ppat.1002191>.
- Chaaand M, Miller KA, Sofia MK, Schlesener C, Weaver JWA, Sood V, Dziejman M. 2015. Type three secretion system island-encoded proteins required for colonization by non-O1/non-O139 serogroup *Vibrio cholerae*. *Infect Immun* 83:2862–2869. <https://doi.org/10.1128/IAI.03020-14>.
- Gotoh K, Kodama T, Hiyoshi H, Izutsu K, Park K-S, Dryselius R, Akeda Y, Honda T, Iida T. 2010. Bile acid-induced virulence gene expression of *Vibrio parahaemolyticus* reveals a novel therapeutic potential for bile acid sequestrants. *PLoS One* 5:e13365. <https://doi.org/10.1371/journal.pone.0013365>.
- Livny J, Zhou X, Mandlik A, Hubbard T, Davis BM, Waldor MK. 2014. Comparative RNA-Seq based dissection of the regulatory networks and environmental stimuli underlying *Vibrio parahaemolyticus* gene expression during infection. *Nucleic Acids Res* 42:12212–12223. <https://doi.org/10.1093/nar/gku891>.

32. Naka H, Dias GM, Thompson CC, Dubay C, Thompson FL, Crosa JH. 2011. Complete genome sequence of the marine fish pathogen *Vibrio anguillarum* harboring the pJM1 virulence plasmid and genomic comparison with other virulent strains of *V. anguillarum* and *V. ordalii*. *Infect Immun* 79:2889–2900. <https://doi.org/10.1128/IAI.05138-11>.
33. Kamruzzaman M, Bhoopong P, Vuddhakul V, Nishibuchi M. 2008. Detection of a functional insertion sequence responsible for deletion of the thermostable direct hemolysin gene (*tdh*) in *Vibrio parahaemolyticus*. *Gene* 421:67–73. <https://doi.org/10.1016/j.gene.2008.06.009>.
34. Dong X, Li N, Liu Z, Lv X, Shen Y, Li J, Du G, Wang M, Liu L. 2020. CRISPRi-guided multiplexed fine-tuning of metabolic flux for enhanced lacto-N-neotetraose production in *Bacillus subtilis*. *J Agric Food Chem* 68:2477–2484. <https://doi.org/10.1021/acs.jafc.9b07642>.
35. Zimmermann L, Stephens A, Nam S-Z, Rau D, Kübler J, Lozajic M, Gabler F, Söding J, Lupas AN, Alva V. 2018. A completely reimplemented MPI bioinformatics toolkit with a new HHpred server at its core. *J Mol Biol* 430:2237–2243. <https://doi.org/10.1016/j.jmb.2017.12.007>.
36. Lobley A, Sadowski MI, Jones DT. 2009. pGenTHREADER and pDomTHREADER: new methods for improved protein fold recognition and superfamily discrimination. *Bioinformatics* 25:1761–1767. <https://doi.org/10.1093/bioinformatics/btp302>.
37. Grishin AM, Cherney M, Anderson DH, Phanse S, Babu M, Cygler M. 2014. NleH defines a new family of bacterial effector kinases. *Structure* 22:250–259. <https://doi.org/10.1016/j.str.2013.11.006>.
38. Grishin AM, Beyrakhova KA, Cygler M. 2015. Structural insight into effector proteins of Gram-negative bacterial pathogens that modulate the phosphoproteome of their host. *Protein Sci* 24:604–620. <https://doi.org/10.1002/pro.2636>.
39. Grishin A, Cherney M, Condos T, Barber K, Anderson D, Phanse S, Babu M, Shaw G, Cygler M. 2014. Bacterial effector kinases. *Acta Crystallogr Sect A* 70:C428. <https://doi.org/10.1107/S2053273314095710>.
40. Pham TH, Gao X, Tsai K, Olsen R, Wan F, Hardwidge PR. 2012. Functional differences and interactions between the *Escherichia coli* type III secretion system effectors NleH1 and NleH2. *Infect Immun* 80:2133–2140. <https://doi.org/10.1128/IAI.06358-11>.
41. García-Angulo VA, Deng W, Thomas NA, Finlay BB, Puente JL. 2008. Regulation of expression and secretion of NleH, a new non-locus of enterocyte effacement-encoded effector in *Citrobacter rodentium*. *J Bacteriol* 190:2388–2399. <https://doi.org/10.1128/JB.01602-07>.
42. Kim DW, Lenzen G, Page A-L, Legrain P, Sansonetti PJ, Parsot C. 2005. The *Shigella flexneri* effector OspG interferes with innate immune responses by targeting ubiquitin-conjugating enzymes. *Proc Natl Acad Sci U S A* 102:14046–14051. <https://doi.org/10.1073/pnas.0504466102>.
43. Matsumoto H, Young GM. 2006. Proteomic and functional analysis of the suite of Ysp proteins exported by the Ysa type III secretion system of *Yersinia enterocolitica* Biovar 1B. *Mol Microbiol* 59:689–706. <https://doi.org/10.1111/j.1365-2958.2005.04973.x>.
44. Yang J, Yan R, Roy A, Xu D, Poisson J, Zhang Y. 2015. The I-TASSER Suite: protein structure and function prediction. *Nat Methods* 12:7–8. <https://doi.org/10.1038/nmeth.3213>.
45. Matlowska-Wasowska K, Finn R, Mustel A, O'Byrne CP, Baird AW, Coffey ET, Boyd A. 2010. The *Vibrio parahaemolyticus* type III secretion systems manipulate host cell MAPK for critical steps in pathogenesis. *BMC Microbiol* 10:329. <https://doi.org/10.1186/1471-2180-10-329>.
46. Alam A, Miller KA, Chaand M, Butler JS, Dziejman M. 2011. Identification of *Vibrio cholerae* type III secretion system effector proteins. *Infect Immun* 79:1728–1740. <https://doi.org/10.1128/IAI.01194-10>.
47. Okada N, Matsuda S, Matsuyama J, Park K-S, de los Reyes C, Kogure K, Honda T, Iida T. 2010. Presence of genes for type III secretion system 2 in *Vibrio mimicus* strains. *BMC Microbiol* 10:302. <https://doi.org/10.1186/1471-2180-10-302>.
48. Grishin AM, Barber KR, Gu R-X, Tieleman DP, Shaw GS, Cygler M. 2018. Regulation of *Shigella* effector kinase OspG through modulation of its dynamic properties. *J Mol Biol* 430:2096–2112. <https://doi.org/10.1016/j.jmb.2018.05.015>.
49. Pham TH, Gao X, Singh G, Hardwidge PR. 2013. *Escherichia coli* virulence protein NleH1 interaction with the v-Crk sarcoma virus CT10 oncogene-like protein (CRKL) governs NleH1 inhibition of the ribosomal protein S3 (RPS3)/nuclear factor  $\kappa$ B (NF- $\kappa$ B) pathway. *J Biol Chem* 288:34567–34574. <https://doi.org/10.1074/jbc.M113.512376>.
50. Blondel CJ, Park JS, Hubbard TP, Pacheco AR, Kuehl CJ, Walsh MJ, Davis BM, Gewurz BE, Doench JG, Waldor MK. 2016. CRISPR/Cas9 screens reveal requirements for host cell sulfation and fucosylation in bacterial type III secretion system-mediated cytotoxicity. *Cell Host Microbe* 20:226–237. <https://doi.org/10.1016/j.chom.2016.06.010>.
51. Hiyoshi H, Kodama T, Iida T, Honda T. 2010. Contribution of *Vibrio parahaemolyticus* virulence factors to cytotoxicity, enterotoxigenicity, and lethality in mice. *Infect Immun* 78:1772–1780. <https://doi.org/10.1128/IAI.01051-09>.
52. Zhou X, Ritchie JM, Hiyoshi H, Iida T, Davis BM, Waldor MK, Kodama T. 2012. The hydrophilic translocator for *Vibrio parahaemolyticus*, T3SS2, is also translocated. *Infect Immun* 80:2940–2947. <https://doi.org/10.1128/IAI.00402-12>.
53. Katoh K, Rozewicki J, Yamada KD. 2019. MAFFT online service: multiple sequence alignment, interactive sequence choice and visualization. *Brief Bioinform* 20:1160–1166. <https://doi.org/10.1093/bib/bbx108>.
54. Notredame C, Higgins DG, Heringa J. 2000. T-Coffee: a novel method for fast and accurate multiple sequence alignment. *J Mol Biol* 302:205–217. <https://doi.org/10.1006/jmbi.2000.4042>.
55. Robert X, Gouet P. 2014. Deciphering key features in protein structures with the new ENDscript server. *Nucleic Acids Res* 42:W320–W324. <https://doi.org/10.1093/nar/gku316>.
56. Crooks GE, Hon G, Chandonia J-M, Brenner SE. 2004. WebLogo: a sequence logo generator. *Genome Res* 14:1188–1190. <https://doi.org/10.1101/gr.849004>.
57. Darling ACE, Mau B, Blattner FR, Perna NT. 2004. Mauve: multiple alignment of conserved genomic sequence with rearrangements. *Genome Res* 14:1394–1403. <https://doi.org/10.1101/gr.2289704>.
58. Bertelli C, Laird MR, Williams KP, Simon Fraser University Research Computing Group, Lau BY, Hoard G, Winsor GL, Brinkman FS. 2017. IslandViewer 4: expanded prediction of genomic islands for larger-scale datasets. *Nucleic Acids Res* 45:W30–W35. <https://doi.org/10.1093/nar/gkx343>.
59. Carver T, Harris SR, Berriman M, Parkhill J, McQuillan JA. 2012. Artemis: an integrated platform for visualization and analysis of high-throughput sequence-based experimental data. *Bioinformatics* 28:464–469. <https://doi.org/10.1093/bioinformatics/btr703>.
60. Kumar S, Stecher G, Tamura K. 2016. MEGA7: Molecular Evolutionary Genetics Analysis version 7.0 for bigger datasets. *Mol Biol Evol* 33:1870–1874. <https://doi.org/10.1093/molbev/msw054>.
61. Letunic I, Bork P. 2019. Interactive Tree Of Life (iTOL) v4: recent updates and new developments. *Nucleic Acids Res* 47:W256–W259. <https://doi.org/10.1093/nar/gkz239>.
62. Buchan DWA, Jones DT. 2019. The PSIPRED Protein Analysis Workbench: 20 years on. *Nucleic Acids Res* 47:W402–W407. <https://doi.org/10.1093/nar/gkz297>.
63. Schrödinger LLC. 2021. Schrödinger release 2020-4: Maestro. Schrödinger, LLC, New York, NY.
64. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. 1990. Basic local alignment search tool. *J Mol Biol* 215:403–410. [https://doi.org/10.1016/S0022-2836\(05\)80360-2](https://doi.org/10.1016/S0022-2836(05)80360-2).
65. Sullivan MJ, Petty NK, Beatson SA. 2011. Easyfig: a genome comparison visualizer. *Bioinformatics* 27:1009–1010. <https://doi.org/10.1093/bioinformatics/btr039>.